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Patients with Tangier disease exhibit extremely low plasma HDL concentrations resulting from mutations in 
the ATP-binding cassette, sub-family A, member 1 (ABCA1) protein. ABCA1 controls the rate-limiting step in 
HDL particle assembly by mediating efflux of cholesterol and phospholipid from cells to lipid-free apoA-I, 
which forms nascent HDL particles. ABCA1 is widely expressed; however, the specific tissues involved in HDL 
biogenesis are unknown. To determine the role of the liver in HDL biogenesis, we generated mice with targeted 
deletion of the second nucleotide-binding domain of Abca1 in liver only (Abca1–L/–L). Abca1–L/–L mice had total 
plasma and HDL cholesterol concentrations that were 19% and 17% those of wild-type littermates, respec-
tively. In vivo catabolism of HDL apoA-I from wild-type mice or human lipid-free apoA-I was 2-fold higher in 
Abca1–L/–L mice compared with controls due to a 2-fold increase in the catabolism of apoA-I by the kidney, with 
no change in liver catabolism. We conclude that in chow-fed mice, the liver is the single most important source 
of plasma HDL. Furthermore, hepatic, but not extrahepatic, Abca1 is critical in maintaining the circulation of 
mature HDL particles by direct lipidation of hepatic lipid-poor apoA-I, slowing its catabolism by the kidney 
and prolonging its plasma residence time.
Introduction
HDL cholesterol (HDL-C) concentration is inversely proportional 
to cardiovascular disease risk (1). This relationship is thought to 
be mediated by the ability of HDL to transport excess cholesterol 
from peripheral tissues back to the liver for excretion in a process 
known as reverse cholesterol transport (RCT) (2). An understand-
ing of the molecular events in HDL formation is necessary for the 
development of therapeutic strategies to raise HDL-C levels and 
protect against atherosclerosis.
HDL biogenesis is poorly understood. Initially, HDL particle for-
mation was thought to occur inside the cell, by a process similar 
to that for the formation of VLDL and LDL particles (3). However, 
the assembly of free cholesterol (FC) and phospholipid (PL) with 
lipid-free apoA-I to form nascent HDL particles is now thought to 
occur extracellularly (3–5). Fibroblasts from patients with Tangier 
disease are unable to assemble PL and FC with apoA-I (6), and 
these patients are characterized by a near absence of plasma HDL 
and the accumulation of cholesterol esters in tissues enriched with 
macrophages (7). The discovery that mutations in the (ATP-binding 
cassette, sub-family A, member 1) ABCA1 gene cause Tangier disease 
and familial hypoalphalipoproteinemia has clearly established 
ABCA1 as the key protein responsible for the assembly of FC and 
PL with lipid-free apoA-I and a critical molecule regulating an ini-
tial step in RCT and nascent HDL particle assembly (8–10).
According to the traditional model of RCT, HDL-C originates 
from peripheral tissues and is subsequently transferred to the liver 
(2). However, recent studies have challenged this model based on the 
finding of overexpression of ABCA1 by the liver, which raised plasma 
HDL concentrations and suggested that significant HDL particle 
assembly occurred at the hepatocyte surface (11–13). In addition, 
bone marrow transplantation studies revealed that the macrophage 
is not a significant source of plasma HDL-C (14). Furthermore, only 
2 tissues, the liver and intestine, are quantitatively important in the 
synthesis and secretion of apoA-I (15). These findings suggest that 
the liver may be a significant source of HDL particles. However, the 
contribution of the liver to HDL biogenesis is unknown.
To definitively determine the role of hepatic Abca1 in HDL 
particle formation and catabolism, we developed liver-specific 
Abca1-knockout mice (Abca1–L/–L) by gene targeting. Our results 
demonstrate that hepatic Abca1 is essential for the lipidation 
of nascent apoA-I and the maintenance of the majority of the 
plasma HDL pool.
Results
Creation of liver-specific Abca1-knockout mice. Conditional targeting 
of the mouse Abca1 gene was achieved by flanking exons 45–46, 
which encode the second nucleotide-binding fold, with loxP sites, 
as depicted in Figure 1A (Floxed allele). Tissue-specific expression 
of Cre recombinase is predicted to eliminate exons 45–46 and result 
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in an inactive Abca1 protein. Eight of 267 embryonic stem cell 
clones surviving selection with G418 and ganciclovir were found to 
be correctly targeted by PCR and Southern blot analysis. However, 
only 2 of the correctly targeted clones were observed to have the 
loxP site in intron 46 after homologous recombination. This was 
determined by PCR amplification of a 500-bp fragment of genomic 
DNA including the HindIII site of intron 46, followed by DNA 
sequencing of the agarose gel–isolated PCR product. One of these 
clones was used to develop the mice described in this article.
The initial genotyping of mice was performed by PCR analysis 
of tail DNA, and presumptive genotypes were assigned to animals 
based on coinheritance of the Cre transgene, under control of the 
albumin promoter for liver-specific expression, and wild-type or 
floxed Abca1 alleles. To verify the initial genotypic assignment, we 
performed Southern blot analysis of genomic DNA from liver and 
kidney when animals were killed. Only the 6-kb wild-type allele was 
observed in DNA from liver and kidney in wild-type mice (Figure 
1B, lanes 1 and 2). In heterozygous mice, both floxed and wild-type 
alleles were present in kidney DNA; however, liver DNA showed the 
presence of the predicted knockout allele (4 kb) and some residual 
floxed allele (7 kb), as well as the wild-type allele (6 kb) (lanes 3 and 
4). In homozygous mice, only the floxed allele was observed in the 
kidney, but the liver contained predominantly the knockout allele 
(70% based on PhosphorImager analysis; lane 6) and some resid-
ual floxed allele (30%). We attribute the residual floxed allele to 
genomic DNA from nonhepatic cells (Kupffer, endothelial, white 
Figure 1
Targeting strategy and genotypic analysis of liver-specific Abca1-knockout mice. (A) Schematic of 3′ region (exons 44–49) of Abca1 gene 
showing wild-type (top), floxed (middle), and knockout (bottom) Abca1 alleles. Three loxP sites, 2 flanking the neomycin (Neo) resistance gene 
and 1 in intron 46, are shown as arrowheads. Arrows below the floxed allele indicate relative position of primers used for PCR screen of alleles. 
The size of the EcoRV (RV) fragment is shown above each allele, and the relative location of the probe used for Southern blot analysis is shown 
above the wild-type allele (Probe A). Cre recombinase–mediated elimination of exons 45 and 46 will delete the second ATP-binding cassette, 
resulting in a knockout allele. Restriction sites: Bg2, Bgl II; E, EcoRI; H, HindIII; S, SacI. (B) Southern blot analysis of liver (L) and kidney (K) 
genomic DNA from mice that inherited both the Cre and wild-type or floxed Abca1 alleles. DNA was digested with EcoRV and hybridized with 
probe A. –L denotes a liver-specific knockout allele. (C) Quantitative real-time PCR analysis of RNA isolated from liver and kidney. Relative fold 
change compared with a wild-type (+/+) liver sample was calculated using the 2–ΔΔCT method (42). (D) Western blot analysis of liver membranes 
isolated from 3 mice of the indicated Abca1 genotypes. (E) Multi-tissue Southern blot of genomic DNA from the indicated tissues from a wild-type 
and liver-specific knockout (–L/–L) mouse.
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blood cells, etc.) in the liver sample, as described in other liver-spe-
cific knockout mice (16). Results from quantitative real-time PCR 
analysis of Abca1 mRNA demonstrated a gene dosage–dependent 
decrease in mRNA, to 30% of normal for Abca1–L/–L mice compared 
with wild-type littermates, in the liver but not in the kidney (Figure 
1C). Western blot analysis of liver membranes also showed a gene 
dosage–dependent decrease in Abca1 protein to near undetectable 
levels in the homozygous knockout mice (Figure 1D). Multi-tissue 
Southern blot analysis demonstrated that only the liver DNA from 
Abca1–L/–L mice contained the knockout allele, whereas other tis-
sues from this animal had only the floxed allele, and all tissues in 
the wild-type littermate control had only the wild-type allele (Fig-
ure 1E). These data show that Abca1 recombination and targeted 
deletion were specific for liver.
PC and FC efflux from primary hepatocytes and elicited peritoneal 
macrophages. To ensure that the recombination of the floxed allele 
resulted in loss of Abca1 function, we isolated and cultured pri-
mary hepatocytes from Abca1–L/–L and Abca1+/+ mice and stimu-
lated them with liver X receptor/retinoid X receptor (LXR/RXR) 
agonists prior to performing PC and FC efflux studies. FC (Figure 
2A) and PL (Figure 2B) efflux from hepatocytes in the absence of 
lipid-free apoA-I was similar for both genotypes. However, in the 
presence of apoA-I, there was a significant (P < 0.01) stimulation 
of efflux for both lipids with hepatocytes derived from wild-type 
mice compared with those from Abca1–L/–L mice. In addition, no 
Abca1 protein was detected in hepatocytes from the knockout 
mice, whereas abundant protein was detected in wild-type controls 
(Figure 2D, top panel). These data confirm that our liver-specific 
knockout mice had no residual apoA-I–dependent Abca1 lipid 
efflux activity in hepatocytes. As a control, lipid efflux was mea-
sured in thioglycolate-elicited peritoneal macrophages from mice 
of the same genotype. Macrophages from wild-type and knock-
out mice showed the expected stimulation of cholesterol efflux 
in the presence of apoA-I and with additional treatment with 
the LXR agonist, T0901317 (Figure 2C). However, regardless of 
the experimental condition, efflux of cholesterol was similar for 
macrophages from wild-type and Abca1–L/–L mice. Abca1 protein 
expression was also similar for cultured elicited macrophages from 
mice of both genotypes (Figure 2D, bottom).
Birth frequency of genotypes. Previous studies have documented 
that matings of homozygous Abca1-knockout (Abca1–/–) are non-
productive and lead to neonatal death as a result of placental 
malformation and fetal distress (17, 18). Consistent with these 
observations, we found the frequency of genotypes of our total 
Abca1-knockout (Abca1–/–) mice generated from intercross mat-
ings of Abca1+/–EIIa-Cre transgenic mice did not follow Mendelian 
inheritance (Abca1+/+, 18%; Abca1+/–, 69%; and Abca1–/–, 13%; n = 21). 
However, in the case of the liver-specific knockout, the frequency of 
genotypes derived from intercross matings of heterozygous liver-
specific Abca1-knockout mice that inherited the Cre recombinase 
transgene (i.e., Abca+/–L(flox)Alb-Cre Tg) was close to that expected for 
Mendelian inheritance (Abca1+/+, 22%; Abca1+/–L, 44%; and Abca1–L/–L, 
33%; n = 72), which indicates that neither absence of hepatic Abca1 
nor reduced HDL-C levels are responsible for the decreased fertil-
ity observed in Abca1–/– mice (19).
Plasma lipid and lipoprotein analysis. The plasma lipid and lipopro-
tein phenotype for chow-fed liver-specific Abca1 and Abca1–/– mice 
after a 4-hour fast is shown in Table 1. Total and HDL-C concen-
trations in plasma of Abca1–L/–L mice were 80% lower than those of 
wild-type littermates (P < 0.001). Plasma FC, esterified cholesterol, 
and PL were all markedly lower in concentration (70–90% reduc-
tion) in Abca1–L/–L mice compared with wild-type animals, and 
plasma triglyceride (TG) concentrations were significantly higher, 
which is consistent with the phenotype in Tangier disease patients 
(7). Plasma apoA-I, measured by ELISA, was also 90% lower in 
Abca1–L/–L mice. Values for heterozygous mice were intermediate to 
those of wild-type and homozygous liver-specific knockout mice, 
which confirms a gene dosage effect of hepatic Abca1 expression 
on plasma lipid and HDL-C concentrations. Values for Abca1–/– 
mice, generated using EIIa-Cre transgenic mice, were slightly lower 
than those for Abca1–L/–L mice. Lecithin cholesterol acyltransferase 
(LCAT) and hepatic lipase (HL) activities in plasma were 50% lower 
in Abca1–L/–L compared with wild-type littermates (Table 1). How-
ever, PL transfer protein (PLTP) activity was reduced to background 
levels (i.e., equivalent to that in plasma of PLTP-knockout control 
mice; courtesy of Xian-Cheng Jiang, SUNY Downstate Medical Cen-
ter, New York, New York, USA) in the Abca1–L/–L mice (Table 1).
Lipoprotein particle analysis. Given the striking decrease in plas-
ma HDL-C levels of Abca1–L/–L mice as determined by the hepa-
Figure 2
Lipid efflux from primary hepatocytes and peritoneal macrophages. 
Primary mouse hepatocytes were isolated from chow-fed Abca1+/+ or 
Abca1–L/–L mice, stimulated with 9-cis-retanoic acid and 22-OH-cho-
lesterol, and radiolabeled with either [3H]cholesterol or [14C]choline 
chloride for 24 hours. After an hour of equilibration, cells were incu-
bated in the presence or absence of 10 μg apoA-I/ml for 24 hours. (A) 
Hepatocyte cholesterol efflux in the presence or absence of apoA-I. 
(B) Hepatocyte choline PL efflux in the presence or absence of apoA-I. 
Data with unlike symbols are significantly different from one another 
(P < 0.05). (C) Thioglycolate-elicited peritoneal macrophages were iso-
lated from Abca1+/+ or Abca1–L/–L mice, radiolabeled with [3H]cholesterol 
for 24 hours, and then incubated with 10 μM T0901317 or vehicle for 
an additional 24 hours. Cholesterol efflux was measured after 24-hour 
incubation of cells, which were stimulated with T0901317 or vehicle in 
the presence or absence of 20 μg apoA-I/ml. Radiolabel in medium 
and the cellular isopropanol extract was quantified, and percentage 
efflux was calculated as the ratio of radioactivity in the medium divided 
by total radioactivity (cells + media) × 100%. Data are mean ± SD for 
3 mice of the indicated genotypes, assayed in triplicate. (D) Western 
blot of Abca1 or load control protein (GAPDH or β-actin) in cultured 
hepatocytes (top) or cultured elicited macrophages (bottom).
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rin-manganese precipitation method, we investigated the size 
distribution and apolipoprotein content of the plasma lipopro-
teins. The distribution of cholesterol among lipoproteins after 
fractionation of plasma by fast performance lipid chromatogra-
phy (FPLC) confirmed the profound reduction in HDL-C con-
centrations in Abca1–L/–L mice compared with wild-type controls 
(Figure 3A). The FPLC cholesterol elution profile also suggested 
a slight shift of the curve to the right in elution time of HDL par-
ticles for Abca1+/–L and Abca1–L/–L compared with wild-type mice, 
which suggests that the average size of HDL particles was smaller 
in these animals. However, nondenaturing gradient PAGE and 
apoA-I Western blot analysis revealed a similar size distribution 
for HDL particles in plasma of all 3 genotypes, which suggests 
that the decrease in plasma HDL concentration was due primar-
ily to a decrease in the number of similar-sized particles (Figure 
3B). There was also a decrease in cholesterol concentration in the 
LDL elution region of the FPLC column for heterozygous and 
homozygous mice, which is consistent with reported decreases 
in LDL concentration in patients with Tangier disease and in 
Abca1–/– mice (7, 18, 20).
To determine whether the apolipoprotein distribution of plasma 
lipoprotein particles was modified in Abca1–L/–L mice, we isolated 
by ultracentrifugation and analyzed them by SDS-PAGE (Figure 
3C). Overall, the apolipoprotein pattern among genotypes was 
similar except for an increase in the proportion of apoB48, albu-
min, and apoA-IV (by Western blot analysis; data not shown) and 
a relative decrease in apoA-I for Abca1–L/–L mice. These data, as well 
as the increase in plasma TG concentration (Table 1), suggest a 
modest accumulation of remnant lipoproteins of intestinal origin 
in the plasma of chow-fed liver-specific knockout mice.
Relationship of hepatic Abca1 expression and plasma HDL-C concentra-
tions. To investigate the relationship between hepatic Abca1 pro-
tein expression and the steady-state concentration of plasma HDL 
among genotypes of liver-specific Abca1-knockout mice, we ana-
lyzed hepatic membrane Abca1 protein expression by Western blot 
analysis for a subset of mice and compared the results with the 
plasma concentration of HDL-C. There was a gene dosage effect 
on hepatic Abca1 protein expression (Figure 4A) that paralleled 
the decrease in plasma HDL-C concentration among liver-specific 
genotypes (Figure 4B), which suggests that the liver is the major 
source of plasma HDL particles in these chow-fed mice.
Plasma turnover and tissue uptake of wild-type HDL particles in liver-
specific Abca1-knockout mice. Although ABCA1 is not thought to play 
a major role in the maturation and metabolism of mature plasma 
HDL particles (21), intravenously injected radiolabeled HDL from 
normal donors is rapidly cleared in patients with Tangier dis-
ease (20, 22), which suggests that ABCA1 may play a role in HDL 
catabolism. Similar observations have been made in studies on the 
Wisconsin hypoalpha mutant (WHAM) chicken, an animal model 
of Tangier disease in which the Abca1 gene is functionally inactive 
(23, 24). We isolated HDL particles that were homogeneous in size 
from wild-type mice and radiolabeled them with [125I]tyramine 
cellobiose ([125I]TC), a residualizing reagent (25), to trace plasma 
decay and tissue uptake of HDL. The tracer HDL particles were 
10.8 nm in diameter, and more than 80% of the radiolabeled pro-
tein migrated as apoA-I (Figure 5A). The radiolabeled HDL par-
ticles were injected into Abca1+/+, Abca1+/–L, and Abca1–L/–L recipient 
mice, and plasma decay of radiolabeled tracer was followed for 
24 hours before the animals were sacrificed and tissues removed 
for quantification of tracer particle uptake. The plasma decay of 
radiolabeled tracer was more rapid with progressive inactivation of 
liver Abca1 alleles (Figure 5B). Abca1–L/–L mice had a 2-fold greater 
tracer fractional catabolic rate (FCR) compared with wild-type 
littermate recipient mice (2.88 ± 0.14 vs. 1.68 ± 0.61 pools/day; 
P < 0.02), whereas heterozygous recipient mice had an interme-
diate FCR (2.00 ± 0.12 pools/day) (Figure 5C). Production rate, 
calculated as the product of plasma apoA-I pool size and plasma 
FCR, was 10-fold higher in wild-type compared with Abca1–L/–L 
mice (3.1 ± 1.7 vs. 0.33 ± 0.09 mg apoA-I/d; P < 0.03). We interpret 
this as the production rate of HDL particles, since apoA-I synthesis 
and secretion are normal in Tangier patients, Abca1–/– mice, and 
the WHAM chicken (7, 24, 26). Monitoring of HDL tracer size in 
plasma during the 24-hour turnover by nondenaturing gradient 
PAGE and PhosphorImager analysis showed no discernible shift 
in HDL particle size (Figure 5D), which suggests that HDL par-
ticles were catabolized from plasma without major remodeling. 
Previous studies have shown that the major sites for HDL apoA-I 
uptake are the liver and kidney (27–29). Uptake of tracer HDL by 
the liver, which included tracer that was recovered in the intestine 
and intestinal contents (30), was not different among genotypes 
and was nearly 3-fold greater than that observed for kidney uptake 
in wild-type mice (19.3% vs. 7.3%; Figure 5E). However, there was a 
Table 1
Plasma measurements of liver-specific and Abca1–/– mice
Abca1  TPC HDL-C FC EC PL TG apoA-I LCATA HLB PLTP
genotype (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl)   (AU)
+/+ 109 ± 17C 88 ± 16C 31 ± 5C 73 ± 21C 164 ± 24C 30 ± 17C 186 ± 67C 58 ± 8C 11 ± 2C 20,635 ± 10,730C
 (27) (22) (6) (6) (7) (7) (3) (3) (5) (5)
+/–L 66 ± 15D 59 ± 11D 19 ± 2D 45 ± 15D 125 ± 26D 28 ± 16C 162 ± 42C 41 ± 5C,D 9 ± 1C 14,948 ± 3,346C
 (18) (9) (7) (7) (9) (7) (3) (3) (5) (5)
–L/–L 19 ± 7E 12 ± 6E 5 ± 2E 12 ± 4E 56 ± 14E 57 ± 17D,E 14 ± 4D  31 ± 8D 5 ± 1D 93 ± 129D
 (17) (17) (7) (7) (7) (7) (3) (3) (5) (5)
–/– 13 ± 0.5E 8 ± 1E 3 ± 3E 10 ± 3E 44 ± 5E 36 ± 6C,E ND ND ND ND
 (3) (3) (3) (3) (3) (3)
Values are mean ± SD. Blood was obtained for analyses from chow-fed mice that were 9–12 weeks old (5–9 wks for Abca1–/– mice), after a 4-hour fast; the 
number of mice analyzed is given in parentheses. +/+, wild type; +/–L, heterozygous liver-specific knockout; –L/–L, homozygous liver-specific knockout; –/–, 
Abca1–/–; EC, esterified cholesterol; ND, not determined; TPC, total plasma cholesterol. ALCAT, nmol cholesteryl ester formed/h/ml plasma; BHL, μmol FA 
released/h/ml plasma. Values in the columns with superscripted letters C–E are significantly different at P < 0.05.
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significant increase in tracer HDL uptake by the kidney with pro-
gressive inactivation of hepatic Abca1 alleles, which resulted in a 
2-fold increase in tracer HDL uptake in Abca1–L/–L compared with 
wild-type mice (12.4% vs. 7.3% of injected dose, respectively).
Plasma turnover and tissue uptake of lipid-free apoA-I in liver-specific 
Abca1-knockout mice. To determine the role of hepatic Abca1 on 
apoA-I catabolism, we performed turnover studies in Abca1-knock-
out mice using purified human lipid-free [125I]TC apoA-I tracer. 
The tracer migrated as authentic apoA-I on a SDS-PAGE gel, with a 
size range of less than 7.1 nm on nondenaturing gradient gels, and 
contained less than 1 molecule of PL per molecule apoA-I (Figure 
6A) (28). Plasma turnover of apoA-I (Figure 6B) was more rapid for 
Abca1–L/–L recipients compared with wild-type mice, with a 2-fold 
greater tracer FCR (3.98 ± 0.34 vs. 1.95 ± 0.04 pools/day, respec-
tively; P < 0.001; Figure 6C). Lipid-free apoA-I tracer FCR was sig-
nificantly higher than that of HDL tracer in Abca1–L/–L mice (3.98 
vs. 2.88 pools/day; P < 0.003), whereas there was no difference in 
plasma FCR for these tracers in wild-type mice (1.95 vs. 1.68 pools/
day, respectively). apoA-I tracer was found to be bound to mouse 
HDL particles in plasma throughout the 24-hour turnover study 
(Figure 6D), with no tracer observed in the migration position of 
lipid-free apoA-I (<7.1 nm; Figure 6A). As observed for the HDL 
turnover study, while there was no difference in liver uptake of 
the apoA-I tracer, there was a 2.3-fold increase in kidney uptake in 
Abca1–L/–L compared with wild-type recipients (Figure 6E). Radio-
label recovery in the liver and intestine was lower in the apoA-I 
tracer turnover study compared with that in the HDL study for 2 
reasons. First, the more rapid removal of [125I]TC apoA-I from the 
plasma compartment compared with [125I]TC HDL likely resulted 
in a greater loss of radiolabel from the liver and kidney into the 
feces and urine during the time course of the turnover (27, 30). 
Second, the liver uptake data in the HDL turnover study included 
radiolabel that had leaked into the intestine (27, 30), whereas the 
apoA-I turnover study did not.
Discussion
Studies in patients with Tangier disease and Abca1-knockout 
mice have shown that efflux of lipid by ABCA1 is the rate-limit-
ing step in HDL particle formation and is absolutely required for 
the maintenance of plasma HDL-C concentrations (18, 20, 31). 
ABCA1 is variably expressed in nearly all tissues of the body, and 
its major function is to assemble FC and PL with lipid-free apoA-I 
to form nascent HDL particles (32). However, only 2 tissues, the 
liver and intestine, synthesize and secrete apoA-I (15). In addi-
tion, adenoviral and transgenic overexpression of hepatic ABCA1 
increases plasma HDL-C concentrations (11–13), which suggests 
that the liver may contribute to the plasma HDL pool. Using a 
liver-specific Abca1-knockout mouse model, we provide what we 
believe to be the first definitive proof that hepatic Abca1 is essen-
tial for approximately 80% of the steady-state pool of plasma HDL 
in chow-fed mice and that the gene dosage–dependent decrease in 
plasma HDL-C is matched by a similar decrease in hepatic Abca1 
protein expression. These results support an unequivocal and 
essential role for hepatic Abca1 in HDL production in an experi-
mental setting in which mice were fed a chow diet and Abca1 was 
not upregulated by cholesterol feeding or LXR activation. The 
finding that plasma HDL-C and apoA-I levels were reduced by 80% 
and 90%, respectively, in the absence of hepatic Abca1 but in the 
presence of functional Abca1 in extrahepatic tissues, also suggests 
that lipidation of the nascent apoA-I molecule occurs during or 
soon after secretion by hepatocytes, prior to entry of the particle 
into the circulation. This finding is in agreement with studies in 
cell culture models, which indicate that hepatocyte lipidation of 
apoA-I occurs in an intra- or pericellular fashion (33, 34). Our data 
also suggest that lipidation by hepatocytes is necessary for main-
Figure 3
Plasma lipoprotein and apolipoprotein characterization of liver-specific 
Abca1-knockout mice. Plasma was obtained from chow-fed Abca1+/+, 
Abca1+/–L, and Abca1–L/–L mice fasted for 4 hours. Equal-volume pools 
of plasma were made using 5 mice of each genotype for FPLC (A) and 
apolipoprotein analysis (C). (A) One hundred microliters whole plas-
ma from each pool was fractionated on Superose 6 FPLC columns. 
Fractions were collected at 1-minute intervals, and total cholesterol 
was measured using an enzymatic assay. (B) One microliter of whole 
plasma from 3 individual mice of each genotype was fractionated on 
a 4–30% nondenaturing gradient gel for 1,400 V/h. The proteins were 
transferred to nitrocellulose, and the blot was developed with anti-
mouse apoA-I antiserum. (C) Pooled plasma from each genotype was 
subjected to ultracentrifugation at a density of 1.25 g/ml to float plasma 
lipoproteins. Fifteen micrograms of lipoprotein protein was added to 
each lane of the gel, and apolipoproteins were separated by 4–16% 
SDS-PAGE. Gels were stained with Coomassie blue and destained to 
visualize the apolipoproteins. Standard low-molecular-weight markers 
(Std) are indicated on the left. Estimated migration position of apoB100, 
apoB48, albumin, apoE, and apoA-I are indicated on the right.
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taining plasma HDL concentrations by prolonging the circulation 
time of HDL apoA-I in vivo.
HDL particle assembly in vivo is complex and poorly under-
stood. The demonstration that fibroblasts from patients with 
Tangier disease are unable to mediate the efflux of FC and PL to 
lipid-free apoAI, and the discovery that mutations in ABCA1 cause 
Tangier disease, established ABCA1 as the key molecule regulating 
the formation of nascent HDL. The identification of the sites of in 
vivo HDL biogenesis is fundamental to our understanding of RCT. 
This pathway, as originally envisioned by Glomset (2), involves the 
release of cellular cholesterol from extrahepatic tissues. Assembly 
of lipid-free apoA-I with PL and FC in peripheral tissues would 
provide a source of nascent HDL particles, which, upon matura-
tion to spherical HDL in plasma by LCAT and PLTP, would direct 
the flux of cholesterol to the liver upon subsequent HDL particle 
catabolism by this organ. However, studies using Abca1-knockout 
bone marrow transplanted into wild-type mice do not support a 
major role for macrophage ABCA1 in the maintenance of plasma 
HDL concentrations (14). Results from our study, involving selec-
tive deletion of hepatic Abca1, demonstrate that the liver is the 
major source of plasma HDL and hepatic Abca1 maintains the 
pool of plasma HDL by lipidating newly secreted apoA-I to pro-
duce nascent HDL particles that undergo maturation in plasma. 
These results therefore profoundly alter our concept of in vivo 
HDL particle assembly by establishing the liver as the single most 
important source of nascent HDL in chow-fed mice.
Since efflux of FC from cells in culture to plasma HDL parti-
cles by non-ABCA1 pathways is quantitatively greater than that 
observed for lipid-free apoA-I by ABCA1 pathways, the main role 
of liver ABCA1 may be to provide plasma HDL particles to par-
ticipate in RCT by pathways other than ABCA1, such as those 
mediated by scavenger receptor class B, type I (SR-BI) and ABCG1 
(35, 36). Efflux of FC from lipid-loaded macrophages by ABCA1 
is an important antiatherogenic pathway of the RCT pathway, 
since transplantation of Abca1–/– macrophages into atherosclero-
sis-susceptible mice results in increased atherosclerosis; however, 
this RCT pathway is not quantitatively important in maintaining 
plasma HDL levels (14, 37, 38). The relative importance of RCT 
via macrophage ABCA1 versus non-ABCA1 HDL efflux pathways 
with regard to atherosclerosis development is unknown and will 
require further investigation.
Normal HDL particles are hypercatabolized in patients with 
Tangier disease and the WHAM chicken (20, 22, 24). Hypercatab-
olism of plasma HDL tracer has been shown to occur even after 
normalization of HDL-C levels in patients with Tangier disease 
(22, 39). We observed an increased turnover of wild-type plasma 
HDL apoA-I in mice with progressive inactivation of hepatic Abca1 
alleles (Figure 5, B and C). However, increased catabolism of the 
tracer was only observed in the kidney, even though the liver was 
responsible for approximately 3-fold more HDL apoA-I catabo-
lism than the kidney in wild-type mice (Figure 5E). These data 
argue against a nonspecific hypercatabolism of the HDL apoA-I 
tracer due to a lower HDL pool size in the Abca1–L/–L mice and are 
compatible with the observation that repletion of the plasma HDL 
pool in Tangier patients does not correct the hypercatabolism of 
HDL. Since HDL particles do not bind to ABCA1 with high affin-
ity and are not efficient acceptors of ABCA1-mediated lipid efflux 
compared to lipid-free apoA-I (21, 40), why should hypercatabo-
lism of normal HDL apoA-I occur in the absence of Abca1? We 
suggest that following selective uptake of HDL cholesteryl ester by 
SR-BI in the liver, lipid-free or lipid-poor apoA-I is released from 
the remodeled HDL particle and immediately relipidated by Abca1 
at the hepatocyte surface before reentry into plasma, which results 
in a renewable source of nascent HDL particles that can enter the 
plasma HDL pool after being processed to mature particles. Our 
data also suggest that functional Abca1 in extrahepatic tissues is 
not sufficient to relipidate and recycle the apoA-I that is released 
at the hepatocyte surface during HDL catabolism, because in the 
absence of hepatic Abca1, lipid-free or lipid-poor apoA-I is not 
relipidated, enters the circulation, and is rapidly cleared by the 
kidney. This argument is also supported by the significantly more 
rapid turnover of lipid-free apoA-I tracer (Figure 6) compared with 
that of HDL tracer (Figure 5) in Abca1–L/–L mice, which suggests 
that extrahepatic Abca1 expression in chow-fed mice is not suf-
ficient to rescue the hypercatabolism of lipid-free apoA-I from 
plasma. Thus, we believe that the maintenance of plasma HDL 
concentrations by hepatic Abca1 is achieved by 2 mechanisms, the 
lipidation of newly secreted hepatic apoA-I and the recycling of 
some proportion of apoA-I after catabolism of HDL particles at 
the hepatocyte surface.
Methods
Generation of liver-specific Abca1-knockout mice. A duplication/deletion target-
ing vector (Osdupdel; courtesy of Oliver Smithies, University of North Car-
olina, Chapel Hill, North Carolina, USA) was used to generate the targeting 
construct. Briefly, the short and long arms of the targeting construct were 
derived from a 6.4-kb BamHI fragment that was detected by screening a 
129/SvEv genomic DNA λ phage library (provided by Hyung-Suk Kim, 
University of North Carolina, Chapel Hill, North Carolina, USA) with a 
PCR-generated probe spanning intron 44 (probe A; Figure 1A). The short 
arm consisted of a 1.2-kb BglII fragment from intron 44, and the long arm 
consisted of a 4.3-kb region from the downstream BglII site of intron 44 
to the EcoRV site in intron 49. A loxP site, in addition to the 2 flanking 
the neomycin resistance gene, was introduced into the targeting vector at 
the HindIII site in intron 46, such that exons 45–46, which encode the 
second nucleotide-binding fold, were flanked by loxP sites (Figure 1A). 
The targeting construct was electroporated into 129/SvEv Tac embryonic 
Figure 4
Hepatic Abca1 protein expression and plasma HDL cholesterol con-
centrations in liver-specific Abca1-knockout mice. Liver membranes 
were isolated from a subset of mice of the indicated genotypes that 
were allowed to consume chow. Membranes were fractionated by SDS-
PAGE, after which proteins were transferred to nitrocellulose mem-
branes and probed with primary antibody to Abca1 or β-actin. Blots 
were developed using a 125I-radiolabeled secondary antibody, and 
PhosphorImager analysis was then used to quantify the signal intensity 
ratio of Abca1 to β-actin (A). HDL cholesterol concentrations in plasma 
were measured by enzymatic assay after precipitation of apoB lipopro-
teins with heparin and MnCl2 (B). Points represent data from individual 
mice, and the horizontal lines denote the mean for each genotype.
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stem cells, which were then subjected to positive and negative selection 
for homologous recombination with G418 and ganciclovir, respectively. 
Surviving embryonic stem cells were screened by PCR and Southern blot 
analysis (see below), and correctly targeted cells were expanded and injected 
into C57BL/6 (B6) mouse blastocysts and implanted into pseudopregnant 
B6 female mice. We bred agouti male mice to B6 female mice to test for 
germline transmission of the conditionally targeted allele (i.e., floxed 
allele). We then made sibling crosses to generate Abca1flox/flox mice and bred 
these mice with B6 mice expressing the Cre transgene under control of the 
albumin promoter (C57BL/6-Tg(Alb-Cre)21Mgn/J; The Jackson Labora-
tory) to generate heterozygous liver-specific 
Abca1-knockout mice (Abca1+/–L); or with B6 
mice expressing the Cre transgene under the 
control of the EIIa promoter (B6.FVB-Tg(EIIa-
Cre) C57379 Lmgd/J; The Jackson Laboratory) 
to generate heterozygous Abca1-knockout 
mice (Abca1+/–). Intercrosses of the latter mice 
(Abca1+/–LAlb-Cre or Abca1+/–EIIa-Cre) were 
made to generate the mice used for this study. 
All animal procedures were approved by the 
Wake Forest University School of Medicine 
Animal Care and Use committee.
PCR, Southern blot, and real-time PCR analysis of 
liver-specific Abca1-knockout mice. We performed 
initial genotyping of offspring by PCR using 
genomic DNA isolated from tail biopsies (41). 
The following primers were used to determine 
the inheritance of the Cre transgene and Abca1 
alleles (+/+, +/flox, flox/flox): Cre 4 forward 
GGACATGTCAGGGATCGCCAGGCG and 
Cre 5 reverse GCATAACCAGTGAAACAG-
CATTGCTG; Abca1 wild-type allele Abc5′ 
GTCCAAGTTCACTACCTGGA and Abc5 
reverse GCAGACTGCCACTTATTCCTC; 
Abca1 floxed allele Abc 5′ and Neo reverse TAT-
GGCGCGCCATCGATCTCGA. Presumptive 
genotypes were assigned based on the PCR 
results, and when animals were sacrificed, 
verification of the genotype was determined 
using Southern blot analysis of genomic 
DNA isolated from liver and other tissues. 
Southern blot analysis was carried out after 
an EcoRV (Promega) digestion of genomic 
DNA isolated from indicated tissues, follow-
ing a proteinase K digestion. Digested DNA 
was fractionated on a 0.8% agarose gel and 
transferred to a Nytran SuperCharge Nylon 
Transfer Membrane (Schleicher & Schuell 
BioScience). Southern blots were hybridized 
with a probe spanning intron 44 (Figure 1A), 
yielding 6-kb, 7-kb, and 4-kb fragments for 
wild-type, floxed, and knockout alleles, respec-
tively. RNA was isolated using TRIzol reagent 
according to the manufacturer’s instruc-
tions (Invitrogen Corp.). RNA was diluted to 
a 1 μg/μl stock and then reverse transcribed 
to generate cDNA that was the template for 
real-time PCR using SYBR Green PCR Mas-
ter Mix (Applied Biosystems) in an ABI Prism 
7700 Sequence Detection System (Applied 
Biosystems). Primers for real-time PCR for Abca1 were: forward (mAbcA1 
198), CGTTTCCGGGAAGTGTCCTA and reverse (mAbcA1 276), GCTAGA-
GATGACAAGGAGGATGGA. Reverse transcription was carried out using 
the Omniscript RT Kit (QIAGEN) with incubation conditions of 37°C for 
60 minutes, followed by denaturation at 95°C for 5 minutes. Data were 
analyzed using the 2–ΔΔCT method (42).
Plasma analyses. We conducted phenotypic measurements using Abca1+/+, 
Abca1+/–L, Abca1–L/–L, and Abca1–/– F2 generation littermates fed a chow diet 
(Prolab RMH 3000 rodent diet; LabDiet). Plasma was isolated from blood 
collected through the tail vein after a 4-hour fast. Plasma lipid concentra-
Figure 5
In vivo catabolism of wild-type HDL tracer in Abca1+/+, Abca1+/–L, and Abca1–L/–L recipient mice. 
HDL particles were isolated from the plasma of chow-fed wild-type mice, radiolabeled with [125I]TC, 
a residualizing reagent, and injected into chow-fed mice of the indicated genotype. Plasma sam-
ples were taken over 24 hours, after which animals were sacrificed, and tissues were harvested 
for quantification of radiolabel uptake. In C and E, genotypes with unlike symbols are significantly 
different from one another (P < 0.05). (A) Characterization of [125I]TC HDL tracer by 4–30% non-
denaturing gradient gel electrophoresis and 4–16% SDS-PAGE. Both gels were visualized by 
PhosphorImager analysis. Standard proteins are shown for reference. (B) Whole plasma die-away 
of wild-type HDL tracer in Abca1+/+, Abca1+/–L, and Abca1–L/–L mice. Individual data points are 
mean ± SD (n = 3). (C) Tracer FCR calculated from the plasma die-away curves in B. The horizon-
tal lines denote the mean for each genotype. (D) Size analysis of [125I]TC HDL tracer in plasma after 
injection into Abca1+/+ and Abca1–L/–L recipient mice. Plasma samples were collected at the indi-
cated times from recipient mice injected with [125I]TC HDL and separated on 4–30% nondenaturing 
gradient PAGE. [125I]TC HDL migration was visualized by PhosphorImager analysis. (E) Liver and 
kidney uptake of [125I]TC HDL tracer 24 hours after injection into Abca1+/+, Abca1+/–L, Abca1–L/–L 
mice. Liver (including intestine and contents; ref. 30) and kidney tissue was digested overnight in 
1 N NaOH at 60°C, and 125I radioactivity in the digest was quantified using a γ-ray counter.
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tions were determined by enzymatic assay (43). To measure plasma HDL-C 
concentration, one-tenth volume of 4% heparin in 2 M MnCl2 was added to 
plasma to precipitate apoB lipoproteins, the plasma was incubated on ice 
for 30 minutes, and the supernatant was isolated after a 1,500-g centrifu-
gation for 30 minutes. Supernatants were assayed for total cholesterol as 
described previously (43).
apoA-I levels were measured by a sandwich ELISA similar to that reported 
previously (44). Briefly, immunoaffinity-purified anti-mouse apoA-I antibody 
(BIODESIGN International) was used for capture and detection, after an ali-
quot was derivatized with HRP. The assay was log-linear from 0.5 to 250 ng 
apoA-I/well, and purified mouse apoA-I (BIODESIGN International) was 
used as standard. Plasma was diluted 2 × 104- to 8 × 104-fold for Abca1+/+ and 
Abca1+/–L mice and 0.25 × 104- to 1 × 104-fold for Abca1–L/–L mice before assay.
LCAT activity in plasma was measured using a recombinant HDL sub-
strate containing 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, cho-
lesterol, and apoA-I as described previously (45). PLTP activity was mea-
sured with a commercially available fluorescent assay kit (Cardiovascular 
Target) following the manufacturer’s instructions. HL activity was mea-
sured in plasma using a radiolabeled triolein–Triton X-100 mixed micellar 
substrate as described previously (46).
Lipoprotein particle characterization. The distribution of plasma lipopro-
teins was determined after fractionation of whole plasma by FPLC using 
two Superose 6 (1 × 30 cm) columns (Amersham Biosciences) in series, fol-
lowed by total cholesterol enzymatic assay of each fraction. To determine 
the size distribution of HDL particles, we applied 1–3 μl of whole plasma 
to a 4–30% nondenaturing gradient gel for electrophoretic separation and 
Western blot analysis as described previously (43). To qualitatively assess 
the apolipoprotein composition of the plasma lipoproteins, we subjected 
200 μl of pooled plasma from each genotype to ultracentrifugation at a 
density of 1.25 g/ml and separated 15 μg of lipoprotein protein by 4–16% 
SDS PAGE as described previously (47). Gels were stained with Coomassie 
blue and destained with acetic acid/methanol to visualize protein bands.
Hepatocyte and macrophage isolation and efflux. Primary hepatocytes were 
isolated from wild-type and Abca1–L/–L mice as previously described (48). 
Briefly, following a liver perfusion with a 0.01% collagenase solution 
through the portal vein, hepatocytes were plated at a 75% confluency 
in DMEM (Invitrogen Corp.) supplemented with 10% FBS (Invitrogen 
Corp.), 20 mU/ml insulin (Novo Nordisk Pharmaceuticals), 1 mM 
sodium pyruvate (Invitrogen Corp.), and 25 nM dexamethasone (Sigma-
Aldrich). The following day, Abca1 expression was stimulated by the 
addition of 20 mM 9-cis-retanoic acid (Sigma-Aldrich) and 8 μg/ml 
22-R-hydroxycholesterol (Steraloids Inc.), and cells were radiolabeled 
with 2 μCi/ml [3H]cholesterol or 10 μCi/ml [3H]choline chloride (Perki-
nElmer). Efflux was performed as previously described (49, 50). Differ-
ences among samples were compared with a 1-way ANOVA test and New-
man-Keuls post-hoc test. Abca1 expression was determined in hepatocyte 
lysates by SDS-PAGE using an anti-Abca1 monoclonal antibody and anti-
GAPDH as loading control, as previously described (32).
Figure 6
In vivo catabolism of human lipid-
free apoA-I tracer in Abca1+/+ and 
Abca1–L/–L recipient mice. apoA-I was 
isolated from human plasma, radiola-
beled with [125I]TC, and injected into 
chow-fed mice of the indicated geno-
type. Details are presented in the 
Figure 5 legend. (A) PhosphorImager 
analysis of [125I]TC apoA-I tracer after 
separation by 4–30% nondenatur-
ing gradient gel electrophoresis and 
4–16% SDS-PAGE. (B) Whole plas-
ma die-away of lipid-free apoA-I trac-
er in Abca1+/+ and Abca1–L/–L mice. 
Individual data points are mean ± SD 
(n = 4). (C) Tracer FCR calculated 
from the plasma die-away curves in B. 
The horizontal lines denote the mean 
for each genotype. (D) Size analysis of 
[125I]TC apoA-I tracer in plasma after 
injection into Abca1+/+ and Abca1–L/–L 
recipient mice. (E) Liver and kidney 
uptake of [125I]TC apoA-I tracer 24 
hours after injection into Abca1+/+ 
and Abca1–L/–L mice. Liver and kidney 
tissue was digested overnight in 1 N 
NaOH at 60°C, and 125I radioactivity in 
the digest was quantified using a γ-ray 
counter. Genotypes with unlike sym-
bols are significantly different from 
one another (P < 0.001).
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Macrophages were obtained from the peritoneal cavity of wild-type and 
Abca1–L/–L mice 4 days after intraperitoneal injection of 1 ml of 10% thio-
glycolate. The cells obtained were washed with Media A (MEM + 10 mM 
HEPES; Cellgro [Mediatech Inc.]), spun at 100 g for 20 minutes, and plated 
in 12-well plates at a density of 6 × 105 cells/well in MEM supplemented 
with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 1% MEM 
vitamin solution 100× (Mediatech Inc.), and 2 mM L-glutamine. Cells 
were washed 2 hours later and incubated for 2 days. On the third day, cells 
were radiolabeled with 2 μCi/ml [3H]cholesterol for 24 hours, washed, and 
incubated with the LXR agonist, 10 μM T0901317 (TO-901317; Sigma-
Aldrich), or vehicle (DMSO) for 24 hours. Cells were incubated with 10 μM 
T0901317 or vehicle for an additional 24 hours in the presence or absence 
of lipid-free apoA-I (20 μg/ml), isolated, and characterized as previously 
described (28). After 24-hour incubation, medium was removed, spun at 
12,500 g for 30 minutes, and assayed for radioactivity. Cells were washed 
with ice-cold PBS, lipids were extracted with isopropanol for 24 hours, and 
the isopropanol extract was assayed for radioactivity.
Abca1 protein expression in macrophages was determined by Western 
blot analysis of total cell protein after lysis of cells in buffer containing 
150 mM NaCl, 25mM Tris-HCl, and 1% Triton X-100. Fifty micrograms of 
total cell protein was incubated at 37°C for 30 minutes and subjected to 
4–16% SDS-PAGE. Proteins were transferred to nitrocellulose membranes 
(Schleicher & Schuell BioScience), and we performed immunodetection 
both for Abca1 using a polyclonal antibody, raised to a 24-mer peptide of 
the C-terminal region of mouse Abca1 conjugated to keyhole limpet hemo-
cyanin, and for β-actin (Sigma-Aldrich), as a load control. Both Abca1 and 
β-actin were visualized using a chemiluminescent reagent (Pierce).
Membrane isolation and Western blot analysis of Abca1 in the liver. Mouse 
liver samples (∼300 mg) were homogenized with a Teflon homogenizer in 
isolation buffer (250 mM sucrose, 10 mM triethanolamine HCl, pH 7.6) 
containing protease inhibitors (0.1 mM PMSF in 95% ethanol, 10 μg/ml 
pepstatin, 10 μg/ml leupeptin, 10 μg/ml aprotinin) for a final concentra-
tion of 10% (wt/vol). Homogenized tissues were centrifuged for 10 min-
utes at 3,300 g at 4°C to pellet cell debris and nuclei. The supernatant was 
recovered and centrifuged again for 20 minutes at 27,000 g at 4°C, and the 
recovered pellet was washed 2 times by resuspension in the original volume 
of isolation buffer followed by centrifugation for 20 minutes at 27,000 g 
at 4°C. After the final resuspension of pellet in isolation buffer, protein 
concentration was determined using the Protein BCA Assay (Pierce).
Western blot analysis was conducted with 100 μg of isolated liver mem-
brane protein, as described above. In this experiment, Abca1 and β-actin 
signals were visualized using 125I-radiolabeled secondary antibody and 
quantified by PhosphorImager (GE Healthcare) analysis. Abca1 protein 
expression was normalized to β-actin for each sample.
Isolation and radioiodination of plasma HDL and apoA-I for turnover studies. 
Whole plasma from wild-type mice was fractionated on a Sepharose CL4B 
column (2 × 50 cm; Amersham Biosciences), and HDL elution position 
was monitored by enzymatic cholesterol assay (28). Individual fractions 
from the column were subjected to 4–30% nondenaturing gradient PAGE. 
Gels were stained and destained, and fractions that contained HDL par-
ticles with minimal albumin contamination were pooled. HDL particles 
were radiolabeled with [125I]TC and subfractionated by size-exclusion 
chromatography using 3 Superdex 200 HR FPLC columns (1 × 30 cm; 
Amersham Biosciences) in series (28). Individual fractions were analyzed by 
4–30% nondenaturing gradient PAGE (1,400 V/h at 10°C), and the size of 
radiolabeled HDL particles was determined by PhosphorImager analysis. 
Individual fractions were pooled to give HDL particles of similar size. The 
specific activity of HDL was 545 cpm/ng protein, and trichloroacetic acid 
(TCA)–precipitable radioactivity was more than 99%.
Lipid-free apoA-I was isolated from human plasma and radiolabeled with 
[125I]TC as described previously (28). The specific activity of the apoA-I 
tracer was 117 cpm/ng protein, and TCA-precipitable radioactivity was 
more than 99%.
In vivo kinetic study. The in vivo kinetic study was performed with [125I]TC-
radiolabeled HDL particles or lipid-free apoA-I as previously described (28). 
Briefly, radiolabeled tracer (4 × 105 to 8 × 105 cpm) was injected into the jug-
ular vein of anesthetized recipient mice, and blood samples were obtained by 
retro-orbital bleeding at 10 and 30 minutes and at 1, 2, 3, 5, 8, and 24 hours. 
Twenty-four hours after dose injection, animals were sacrificed, the vascular 
system was flushed with 15 ml PBS, and the liver, intestine plus contents, 
and kidneys were harvested and digested with 1 N NaOH overnight at 60°C 
prior to 125I radiolabel quantification. FCR of plasma die-away curves was 
calculated using Simulation, Analysis, and Modeling software (SAAM II ver-
sion 1.1.1; SAAM Institute) as described previously (28). 
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